Paragon Capital Management LLC reduced its position in Johnson & Johnson (NYSE:JNJ) by 14.1% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 51,154 shares of the company’s stock after selling 8,407 shares during the period. Johnson & Johnson accounts for about 3.5% of Paragon Capital Management LLC’s investment portfolio, making the stock its 12th biggest position. Paragon Capital Management LLC’s holdings in Johnson & Johnson were worth $6,618,000 at the end of the most recent reporting period.
Other large investors have also recently bought and sold shares of the company. Bath Savings Trust Co raised its holdings in shares of Johnson & Johnson by 6.2% in the 2nd quarter. Bath Savings Trust Co now owns 42,275 shares of the company’s stock valued at $5,888,000 after acquiring an additional 2,479 shares in the last quarter. Cox Capital Mgt LLC increased its position in shares of Johnson & Johnson by 0.6% during the 2nd quarter. Cox Capital Mgt LLC now owns 19,920 shares of the company’s stock valued at $2,774,000 after purchasing an additional 113 shares during the last quarter. Baystate Wealth Management LLC increased its position in shares of Johnson & Johnson by 1.3% during the 2nd quarter. Baystate Wealth Management LLC now owns 29,643 shares of the company’s stock valued at $4,131,000 after purchasing an additional 372 shares during the last quarter. Deane Retirement Strategies Inc. increased its position in shares of Johnson & Johnson by 0.7% during the 2nd quarter. Deane Retirement Strategies Inc. now owns 12,379 shares of the company’s stock valued at $1,724,000 after purchasing an additional 85 shares during the last quarter. Finally, Rockland Trust Co. increased its position in shares of Johnson & Johnson by 1.6% during the 2nd quarter. Rockland Trust Co. now owns 152,532 shares of the company’s stock valued at $21,245,000 after purchasing an additional 2,425 shares during the last quarter. Institutional investors own 72.25% of the company’s stock.
Several equities analysts have recently commented on JNJ shares. Royal Bank of Canada reiterated a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, July 16th. Atlantic Securities upgraded Johnson & Johnson from an “underweight” rating to a “neutral” rating in a research report on Wednesday, October 16th. Credit Suisse Group raised their price target on Johnson & Johnson from $158.00 to $163.00 in a research report on Thursday, October 24th. Goldman Sachs Group set a $169.00 price target on Johnson & Johnson and gave the stock a “buy” rating in a research report on Tuesday, August 27th. Finally, Bank of America restated a “hold” rating and set a $150.00 price target on shares of Johnson & Johnson in a research report on Tuesday, July 16th. Six equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $151.64.
JNJ opened at $133.00 on Friday. The stock’s 50 day simple moving average is $130.83 and its 200 day simple moving average is $134.05. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.26 and a quick ratio of 1.00. Johnson & Johnson has a 1 year low of $121.00 and a 1 year high of $148.99. The firm has a market cap of $343.25 billion, a price-to-earnings ratio of 16.26, a PEG ratio of 2.20 and a beta of 0.69.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, October 15th. The company reported $2.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.00 by $0.12. Johnson & Johnson had a return on equity of 39.81% and a net margin of 21.09%. The business had revenue of $20.73 billion for the quarter, compared to analyst estimates of $20.14 billion. During the same period last year, the company earned $2.05 EPS. Johnson & Johnson’s revenue for the quarter was up 1.9% compared to the same quarter last year. As a group, sell-side analysts anticipate that Johnson & Johnson will post 8.65 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be given a $0.95 dividend. The ex-dividend date is Monday, November 25th. This represents a $3.80 dividend on an annualized basis and a dividend yield of 2.86%. Johnson & Johnson’s dividend payout ratio is currently 46.45%.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Story: What are no-load funds?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.